維多珠單抗全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球維多珠單抗市場預計將從2025年的29.5億美元成長至2034年的60.3億美元，2026年至2034年的複合年成長率（CAGR）為8.27%。該市場正經歷顯著成長，主要原因是潰瘍性大腸炎和克隆氏症發炎性腸道疾病的盛行率不斷上升。維多珠單抗憑藉其標靶作用機制和在治療慢性胃腸炎方面的有效性，已成為生物製藥。人們對先進治療方案的認知不斷提高以及診斷率的提升也促進了該藥物的廣泛應用。醫療保健覆蓋範圍的擴大和對生物製藥投資的增加進一步推動了市場發展。

關鍵成長要素包括自體免疫疾病盛行率的上升、對標靶生物製藥需求的增加以及胃腸道疾病治療的進展。醫療服務提供者正日益採用療效和安全性較佳的治療方法進行長期疾病管理。良好的臨床結果和不斷改進的治療指南正在增強市場需求。此外，不斷成長的醫療保健支出和持續的研究活動也支持先進生物製藥的更廣泛應用。

隨著研發不斷推動發炎性腸道疾病治療策略的改進，市場前景依然樂觀。專科醫療服務的普及和意識提升預計將推動市場成長。新劑型的開發和給藥方式的改進可望進一步提升治療的便利性和患者的用藥依從性。隨著醫療系統日益重視生物製藥，預計對維多珠單抗的需求將保持強勁。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球維多珠單抗市場：依給藥途徑分類

• 市場分析、洞察與預測
• 皮下注射
• 靜脈注射

第5章：全球維多珠單抗市場：依治療線分類

• 市場分析、洞察與預測
• 一線治療
• 二線治療

第6章：全球維多珠單抗市場：依適應症分類

• 市場分析、洞察與預測
• 潰瘍性大腸炎（UC）
• 克隆氏症（CD）

第7章 全球維多珠單抗市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 門診治療
• 居家照護

第8章 全球維多珠單抗市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Pfizer Inc
  • Eli Lilly And Company
  • Bristol Myers Squibb
  • UCB Pharma
  • Amgen Inc
  • Roche Holding AG
  • Polpharma Biologics
  • Takeda Pharmaceutical Company Limited

The global vedolizumab market size is expected to reach USD 6.03 Billion in 2034 from USD 2.95 Billion in 2025, growing at a CAGR of 8.27 during 2026-2034.This market has demonstrated significant growth owing to increasing prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Vedolizumab has emerged as an important biologic therapy due to its targeted mechanism of action and effectiveness in managing chronic gastrointestinal inflammation. Growing awareness regarding advanced treatment options and improving diagnosis rates have contributed to higher adoption levels. Expanding healthcare access and increased investment in biologic therapies have further supported market development.

Key growth drivers include rising incidences of autoimmune disorders, growing demand for targeted biologic treatments, and advancements in gastrointestinal disease management. Healthcare providers are increasingly adopting therapies that offer improved efficacy and safety profiles for long-term disease control. Favorable clinical outcomes and expanding treatment guidelines have strengthened market demand. Additionally, increasing healthcare expenditures and ongoing research initiatives are supporting broader utilization of advanced biologic medications.

Future prospects remain promising as research efforts continue to enhance treatment strategies for inflammatory bowel diseases. Expanding access to specialty healthcare services and growing patient awareness are expected to support market growth. The development of new formulations and improved delivery methods may further enhance treatment convenience and adherence. As healthcare systems increasingly prioritize personalized medicine and advanced biologic therapies, demand for vedolizumab is likely to remain strong.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Route of Administration

• Subcutaneous Injection
• Intravenous Infusion

By Treatment Line

• First-Line Therapy
• Second-Line Therapy

By Indication

• Ulcerative Colitis (UC)
• Crohn's Disease (CD)

By End Use

• Hospitals
• Clinics
• Ambulatory Care
• Home Care

COMPANIES PROFILED

• AbbVie Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Eli Lilly and Company, Bristol Myers Squibb, UCB Pharma, Amgen Inc., Roche Holding AG, Polpharma Biologics, Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VEDOLIZUMAB MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Route Of Administration
• 4.2. Subcutaneous Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Intravenous Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VEDOLIZUMAB MARKET: BY TREATMENT LINE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Line
• 5.2. First-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Second-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VEDOLIZUMAB MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Ulcerative Colitis (UC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Crohn's Disease (CD) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VEDOLIZUMAB MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ambulatory Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VEDOLIZUMAB MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Route Of Administration
  • 8.2.2 By Treatment Line
  • 8.2.3 By Indication
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Route Of Administration
  • 8.3.2 By Treatment Line
  • 8.3.3 By Indication
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Route Of Administration
  • 8.4.2 By Treatment Line
  • 8.4.3 By Indication
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Route Of Administration
  • 8.5.2 By Treatment Line
  • 8.5.3 By Indication
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Route Of Administration
  • 8.6.2 By Treatment Line
  • 8.6.3 By Indication
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL VEDOLIZUMAB INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.3 Pfizer Inc
  • 10.2.4 Eli Lilly And Company
  • 10.2.5 Bristol Myers Squibb
  • 10.2.6 UCB Pharma
  • 10.2.7 Amgen Inc
  • 10.2.8 Roche Holding AG
  • 10.2.9 Polpharma Biologics
  • 10.2.10 Takeda Pharmaceutical Company Limited